This study is conducted in 50 subjects diagnosed with locally advanced breast cancer. Neoadjuvant chemotherapy in such tumors is basically used to reduce tumor size. The standard neoadjuvant regimen used, is the combination of doxorubicin, cyclophosphamide and paclitaxel. End point of neoadjuvant chemotherapy is reaching pathologic complete response (pCR). Generally regardless of the neoadjuvant regimen, pCR, considered as a prognostic factor for response to therapy, has been estimated to be 3-46% in different studies. Since pCR can be relevant to patients’ survival rate, efforts to increase this parameter can be beneficial for the patient. The aim of this study is to evaluate a second line neoadjuvant chemotherapy with the hope of increasing pCR in patients that have not reached a complete clinical response after the standard neoadjuvant regimen. Patient’s clinical status and sonography data are parameters used for evaluating clinical response. According to previous studies and data proving the effectiveness of other agents, carboplatin and gemcitabine with the estimated dose of AUC x 5 and 1g/m2 respectively have been selected as the second line regimen. Two to 3 cycles of second line therapy has been planned. Patients are randomly divided to control and intervention groups. The control group will be receiving the standard neoadjuvant chemotherapy and the intervention group will be treated with both standard and second line chemotherapy. The pathologist and statistical analyst will be blind towards studied groups of patients.